Abstract 627P
Background
The prevalence of multiple primary neoplasms has been increasing over time, with primary colorectal cancer and primary prostate cancer being a common coexistence. Notably, a primary prostatic cancer was discovered in approximately one-sixth of men who underwent prostate cancer screening prior to rectal cancer excision. Due to a lack of knowledge about the racial disparity factor in this multiple primary malignancy, our study aims to assess the risk of developing primary prostate cancer between African Americans and Caucasians in patients with colorectal cancer.
Methods
We extracted the data from cancer registries in the Surveillance, Epidemiology, and End Results (SEER) database for patients with primary colorectal cancer from 2000-2020. This allowed us to compare the risk of developing primary prostate cancer between African American and Caucasian individuals. We used MP-SIR session to estimate the SIR (standardized incidence ratios) as observed/expected (O/E), and excess absolute risk (EAR) per 10,000 patients using 95% Confidence intervals (CI), with significant result when p <0.05. The latency exclusion period was set at 0 month.
Results
Among 721,385 patients included in the study with primary colorectal cancer, only 8,943 (1.24%) developed primary prostate cancer (Expected= 8,938.87, O/E= 1.00, p >0.05, 95% CI: 0.98-1.02, EAR= 0.01). Out of these cases, approximately 7,340 (82.1%) were Caucasian individuals who developed primary prostate cancer (Expected= 7,633.79, O/E= 0.96, p <0.05, 95% CI: 0.94-0.98, EAR= -1.03), while only 1,603 (17.9%) were African American individuals who developed primary prostate cancer (Expected= 1,305.08, O/E= 1.23, P <0.05, 95% CI: 1.17-1.29, EAR= 7.82). Notably, at the age of 70-74 years, Caucasian individuals exhibited a significant decrease in the risk of developing primary prostate cancer (O/E= 0.91, P <0.05, EAR= -4.12), whereas African American individuals showed a significant increase in risk at this age (O/E= 1.27, P <0.05, EAR= 14.32).
Conclusions
Our results show a higher risk of developing primary prostate cancer in African American patients compared to Caucasian patients. Further research is needed to better understand the race variations on a genetic basis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
560P - Triple-targeted therapy of dabrafenib, trametinib and osimertinib for the treatment of acquired BRAF V600E mutation after progression on EGFR-TKIs in advanced EGFR-mutant NSCLC
Presenter: Chengdi Weng
Session: Poster Display
Resources:
Abstract
561P - Mechanisms of osimertinib resistance using circulating tumor DNA analyses for EGFR-mutated non-small cell lung cancer, results from ELUCIDATOR: A prospective observational multicenter study
Presenter: Daijiro Harada
Session: Poster Display
Resources:
Abstract
562P - First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort
Presenter: Yan Yu
Session: Poster Display
Resources:
Abstract
563P - Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
Presenter: Jianya Zhou
Session: Poster Display
Resources:
Abstract
564P - Co-occurring EGFR p.E709X mutation affects the treatment response to the third-generation EGFR-TKIs in EGFR p.G719X-mutant patients with advanced NSCLC
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
565P - Genome-guided targeted therapy combination improves survival in patients with advanced EGFR mutation positive NSCLC failing osimertinib
Presenter: Molly Li
Session: Poster Display
Resources:
Abstract
566P - Safety of tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
Presenter: Chong Kin Liam
Session: Poster Display
Resources:
Abstract
567P - Furmonertinib in combination with bevacizumab and intrathecal chemotherapy as later-line re-challenge treatment in EGFR –mutated NSCLC patients with leptomeningeal metastasis after third-generation EGFR-TKIs treatment failure
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
568P - First-line (1L) osimertinib + platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results
Presenter: David Planchard
Session: Poster Display
Resources:
Abstract
569P - Whole-transcriptome sequencing of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals LUAD–like and SCLC–like subsets
Presenter: Chan-Yuan Zhang
Session: Poster Display
Resources:
Abstract